Jennifer, why don't you delve into that a little bit for us?

Absolutely.

In the dosage discovery trial of Rizukuzumab, which was INSPIRE, this was a phase 2B dose-ranging induction study, and the following doses were investigated, 600 milligrams, 1,200 milligrams, and 1,800 milligram IV dosages given at weeks 0, 4, and 8.

Based on these results, including efficacy, safety, and exposure response analyses, the 1,200 milligram IV was then selected for the phase 3 INSPIRE study.

And it's interesting as well that during this phase 2B study, advanced therapy exposed or inadequate responders actually made up the entirety of the study population, which is in contrast to the phase 3 INSPIRE study, which had a balanced mix of both exposed and advanced therapy naive subjects and is what we generally see in a lot of our studies.

So this is essentially looking at our hardest to treat population.

Absolutely.

When we have these two available doses and the efficacy is pretty great for both of them, a lot of the times my patients will ask me, well, what are we choosing? What are you starting me on? Or maybe not even a patient, even just a colleague might come to me and say, what's the right dose? So how do you talk about this with your patients or even your colleagues?